Fig. 5: Inhibition of HMGCR by lovastatin sensitizes radiotherapy in mouse subcutaneous transplant tumors. | Experimental & Molecular Medicine

Fig. 5: Inhibition of HMGCR by lovastatin sensitizes radiotherapy in mouse subcutaneous transplant tumors.

From: Cholesterol biosynthesis induced by radiotherapy inhibits cGAS–STING activation and contributes to colorectal cancer treatment resistance

Fig. 5

BALB/c mice were subcutaneously inoculated with 1 × 106 CT26 cells. Different treatments commenced when the average tumor volume reached 100 mm3, involving a single dose of 6 Gy local tumor irradiation, along with simultaneous oral administration of 20 mg/kg lovastatindaily. a A schematic illustration showing the timeline of the drug treatment and assays. b Tumor volume (mean ± s.e.m.) was measured after radiotherapy every 2 days. c The individual growth profiles of tumors in each group. d Solid tumors were separated after the mice were euthanized. e Tumor weight (mean ± s.e.m.) was measured after the mice were euthanized. f Body weight change (mean ± s.e.m.) was measured after radiotherapy every 2 days. g The tumor tissue paraffin sections were subjected to H&E staining, PCNA and Cleaved-Caspase-3 IHC staining, and TUNEL staining. Scale bar, 50 μm. **P < 0.01; *P < 0.05; ns, not significant.

Back to article page